arrow
N

Nobuyuki Enzan

kyushu university
H指数:15
被引数:933

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Implications of urinary albumin-to-creatinine ratio for subsequent kidney function decline and kidney-related outcomes in patients hospitalized for worsening heart failure: Insights from the JROADHF-NEXT registry

尿白蛋白肌酐比值对因心力衰竭加重住院患者后续肾功能下降及肾脏相关结局的影响:JROADHF-NEXT登记研究的启示

2026-09-300
PRE
Association of in-Hospital Mineralocorticoid Receptor Antagonist Initiation with Outcomes According to guideline-defined eGFR and potassium eligibility in patients with heart failure

住院期间启动盐皮质激素受体拮抗剂与根据指南定义的eGFR和钾离子水平评估的心力衰竭患者预后的关联

2026-09-210
PRE
Genetically Mediated Differences in LDL Cholesterol and Risk of Venous Thromboembolism

基因介导的低密度脂蛋白胆固醇差异与静脉血栓栓塞症风险

2026-08-280
PRE
Multi-ancestry genetic architecture of heart failure subtypes

心力衰竭亚型的多祖先遗传结构

2026-08-130
OA
Temporal comparison of clinical practice and outcomes in heart failure: the JROADHF and JROADHF-NEXT studies

心力衰竭临床实践和结局的时间比较:JROADHF和JROADHF-NEXT研究

2026-08-080
PRE
Genome-wide analysis of heart failure yields insights into disease heterogeneity and enables prognostic prediction in the Japanese population

全基因组分析对心力衰竭的研究揭示了疾病异质性,并使对日本人群的预后预测成为可能。

2025-11-030
OAAI
Goreisan attenuates cardiac hypertrophy and diastolic dysfunction in heart failure with preserved ejection fraction induced by HFD/L-NAME via regulation of ICAT-β-catenin/ERK axis

Goreisan 通过调节 ICAT-β-catenin/ERK 轴,减轻由 HFD/L-NAME 诱导的射血分数保留型心力衰竭中的心肌肥厚和舒张功能障碍。

2025-09-030
OAAI
Association between Sodium-Glucose Co-Transporter-2 Inhibitor Use and Prognosis in Underweight Patients with Diabetes Mellitus and Heart Failure

钠-葡萄糖共转运蛋白-2抑制剂使用与体重过轻的糖尿病合并心力衰竭患者预后的关系

2025-09-020
PRE
Machine Learning Uncovers the Contribution of Rare Genetic Variants and Enhances Risk Prediction for Coronary Artery Disease in the Japanese Population

机器学习揭示了稀有遗传变异的贡献,并增强了日本人群中冠状动脉疾病的风险预测。

2024-11-120
PRE